Evaluation effect of Hydrocortisone on amylase level of patients underwent Endoscopic retrograde cholangiopancreatography

Evaluation effect of intravenous Hydrocortisone on hyperamylasemia of patients underwent Endoscopic retrograde cholangiopancreatography

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201410236388N6

Enrollment

Registered

2014-12-19

Start date

2013-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis. Disease of pancreas, unspecified

Interventions

Intervention 1: Case Group: injection Ampoule hydrocortisone (manufactured by pharmaceutical Exir) 100 mg intravenously at 0.5-1 hours before ERCP. Intervention 2: Control Group: Injection of 2 cc Nor

Treatment - Drugs

Case Group: injection Ampoule hydrocortisone (manufactured by pharmaceutical Exir) 100 mg intravenously at 0.5-1 hours before ERCP

Control Group: Injection of 2 cc Normal saline (Placebo) at 0.5-1 hours before ERCP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria:Highness of Amylase levels (less than three times normal) before ERCP. Exclusion criteria: Developing diabetes; Current or history of corticosteroid use within 2 weeks ago; Developing pancreatitis during the 2 weeks before ERCP; Developing chronic pancreatitis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum Amylase. Timepoint: 2 hours after ERCP. Method of measurement: Check by Laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Amin Sadrazar

Tabriz University of Medical Sciences

a_sadrazar@yahoo.com+98 41 3337 3966

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026